BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20379114)

  • 1. [Marfan syndrome complicated with CD5+ CD10+ diffuse large B-cell lymphoma].
    Yoshitake K; Hagiwara Y; Tanae K; Takahashi N; Kohri M; Tamaru J; Bessho M; Niitsu N
    Rinsho Ketsueki; 2010 Mar; 51(3):196-200. PubMed ID: 20379114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Primary adrenal diffuse large B-cell lymphoma positive for CD5 and CD10].
    Yamamoto Y; Sumii Y; Shiraishi Y; Ikeuchi K; Yamada H; Niiya D; Shiote Y; Yamamoto K; Imajo K
    Rinsho Ketsueki; 2017; 58(2):161-164. PubMed ID: 28321095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
    Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
    Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
    Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
    Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy.
    Ohno T; Sakamoto T; Mizumoto C; Miyoshi T; Ueda M; Takeoka T; Yamashita K; Hishita T; Hada S
    Int J Hematol; 2006 Jul; 84(1):74-8. PubMed ID: 16867907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD5-positive diffuse large B cell lymphoma arising from a CD5-positive follicular lymphoma.
    Vassallo J; Bousquet M; Quelen C; Al Saati T; Delsol G; Brousset P
    J Clin Pathol; 2007 May; 60(5):573-5. PubMed ID: 17513519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
    Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas.
    Manazza AD; Bonello L; Pagano M; Chiusa L; Novero D; Stacchini A; Martini G; Vitolo U; Tarella C; Inghirami G; Palestro G; Chiarle R
    Am J Clin Pathol; 2005 Aug; 124(2):182-90. PubMed ID: 16040287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CD5- and CD10-positive MYC and BCL2 double-expressor diffuse large B-cell lymphoma with MYD88
    Sasaki Y; Murai S; Okamura R; Uesugi Y; Shimada S; Watanuki M; Fujiwara S; Kawaguchi Y; Arai N; Yanagisawa K; Honma M; Yamochi T; Hattori N
    Rinsho Ketsueki; 2023; 64(1):42-48. PubMed ID: 36775306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2.
    Xu Y; McKenna RW; Molberg KH; Kroft SH
    Am J Clin Pathol; 2001 Aug; 116(2):183-90. PubMed ID: 11488064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CD4-positive diffuse large B-cell lymphoma].
    Nakazato T; Suzuki K; Mihara A; Sanada Y; Kakimoto T; Yoshida S
    Rinsho Ketsueki; 2009 Jul; 50(7):568-73. PubMed ID: 19638725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma.
    Yegappan S; Coupland R; Arber DA; Wang N; Miocinovic R; Tubbs RR; Hsi ED
    Mod Pathol; 2001 Nov; 14(11):1147-56. PubMed ID: 11706077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs.
    Ueno S; Yamaguchi M; Kimura M; Odagiri H; Shiraki K; Uemoto S; Nakamura N; Zhang W; Shiku H; Kobayashi T
    Int J Oncol; 2005 Nov; 27(5):1241-6. PubMed ID: 16211218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical analysis of 10 patients with de novo CD5 positive diffuse large B cell lymphoma].
    Zhang Q; Zhang HY; Zhong FL; Zhang WL; Xu L; Feng J; Meng QX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):399-402. PubMed ID: 23628041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.
    Kobayashi T; Yamaguchi M; Kim S; Morikawa J; Ogawa S; Ueno S; Suh E; Dougherty E; Shmulevich I; Shiku H; Zhang W
    Cancer Res; 2003 Jan; 63(1):60-6. PubMed ID: 12517778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Richter syndrome: report of a case].
    Chen DB; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):487-8. PubMed ID: 21055184
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
    Koivula S; Valo E; Raunio A; Hautaniemi S; Leppä S
    Oncol Rep; 2011 Apr; 25(4):1183-90. PubMed ID: 21318224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome.
    Sano T; Sakai H; Takimoto K; Ohno H
    Int J Clin Oncol; 2007 Feb; 12(1):59-62. PubMed ID: 17380444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
    Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
    Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
    Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
    Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.